About Deciphera
Deciphera is a company based in Waltham (United States) founded in 2003 was acquired by ONO PHARMACEUTICAL in April 2024. Deciphera has raised $172.9 million across 3 funding rounds from investors including Lilly, New Leaf Venture Partners and ONO PHARMACEUTICAL. The company has 394 employees as of December 31, 2022. Deciphera offers products and services including Ripretinib, Vimseltinib, DCC-3116, DCC-3084, and DCC-3009. Deciphera operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Waltham, United States
- Employees 394 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Deciphera Pharmaceuticals, Llc
-
Annual Revenue
$163.36 M (USD)22as on Dec 31, 2023
-
Net Profit
-$194.94 M (USD)-9as on Dec 31, 2023
-
EBITDA
-$210.96 M (USD)-15as on Dec 31, 2023
-
Total Equity Funding
$172.9 M (USD)
in 3 rounds
-
Latest Funding Round
$52.3 M (USD), Series C
Jun 05, 2017
-
Investors
Lilly
& 6 more
-
Employee Count
394
as on Dec 31, 2022
-
Acquired by
ONO PHARMACEUTICAL
(Apr 29, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Deciphera
Deciphera offers a comprehensive portfolio of products and services, including Ripretinib, Vimseltinib, DCC-3116, DCC-3084, and DCC-3009.
Kinase inhibitor targeting cancer growth and resistance
Kinase inhibitor for specific cancer treatments
Experimental kinase inhibitor in preclinical stages
Kinase inhibitor for oncology applications
Preclinical kinase inhibitor for cancer therapy
People of Deciphera
Unlock access to complete
Unlock access to complete
Leadership Team
66 people
Software Development Team
33 people
Operations Team
18 people
Senior Team
9 people
Sales and Marketing
7 people
Product Management Team
7 people
Human Resources and Administration
7 people
Finance and Accounting
6 people
Unlock access to complete
Funding Insights of Deciphera
Deciphera has successfully raised a total of $172.9M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $52.3 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Deciphera
Deciphera has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, New Leaf Venture Partners and ONO PHARMACEUTICAL.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on early-stage healthcare startups
|
Locked | Locked | Locked |
Investor details for Deciphera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Deciphera
Investment portfolio details for Deciphera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Deciphera
Detailed financials for Deciphera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Deciphera Comparisons
Peer comparison for Deciphera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Deciphera
Deciphera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Deciphera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Deciphera
Complete news archive for Deciphera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Deciphera
Deciphera was founded in 2003 and raised its 1st funding round 11 years after it was founded.
Deciphera is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Deciphera is a funded company, having raised a total of $172.9M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Deciphera is 394.
Annual revenue of Deciphera is $163.36M as on Dec 31, 2023.
Deciphera was founded in 2003 in Waltham, United States, within the biotechnology sector. A proprietary switch-control kinase inhibitor platform is utilized by the company, combined with expertise in kinase biology, to advance a portfolio of cancer therapies. Focus is placed on type 2 kinase inhibitors aimed at addressing unmet needs in oncology. Operations center on research and development for novel medicinal products in the United States.
Deciphera's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Deciphera offers Ripretinib, Vimseltinib, DCC-3116, DCC-3084, and DCC-3009.
Deciphera has 7 investors. Key investors include Lilly, New Leaf Venture Partners, ONO PHARMACEUTICAL, Viking Global Investors, and Redmile Group.